Clinical data | |
---|---|
Pronunciation | Droe-SPY-re-nown |
Trade names | Alone: Slynd With estradiol: Angeliq With ethinylestradiol: Yasmin, Yasminelle, Yaz, others With estetrol: Nextstellis |
Other names | Dihydrospirenone; Dihydrospirorenone; 1,2-Dihydrospirorenone; MSp; SH-470; ZK-30595; LF-111; 17β-Hydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid, γ-lactone |
AHFS/Drugs.com | Professional Drug Facts |
License data |
|
Routes of administration | By mouth[1] |
Drug class | Progestogen; Progestin; Antimineralocorticoid; Steroidal antiandrogen |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 66–85%[1][4][5] |
Protein binding | 95–97% (to albumin)[3][1][4] |
Metabolism | Liver (mostly CYP450-independent (reduction, sulfation, and cleavage of lactone ring), some CYP3A4 contribution)[4][6][7][8] |
Metabolites | • Drospirenone acid[3] • 4,5-Dihydrodrospirenone 3-sulfate[3] |
Elimination half-life | 25–33 hours[3][4][1] |
Excretion | Urine, feces[3] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.060.599 |
Chemical and physical data | |
Formula | C24H30O3 |
Molar mass | 366.501 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Drospirenone is a progestin and antiandrogen medication which is used in birth control pills to prevent pregnancy and in menopausal hormone therapy, among other uses.[1][9] It is available both alone under the brand name Slynd and in combination with an estrogen under the brand name Yasmin among others.[9][3] The medication is an analog of the drug spironolactone.[10] Drospirenone is taken by mouth.[1][3]
Common side effects include acne, headache, breast tenderness, weight increase, and menstrual changes.[3] Rare side effects may include high potassium levels and blood clots (when taken as a combined oestrogen-progestogen pill), among others.[3][11] Drospirenone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[1] It has additional antimineralocorticoid and antiandrogenic activity and no other important hormonal activity.[1] Because of its antimineralocorticoid activity and lack of undesirable off-target activity, drospirenone is said to more closely resemble bioidentical progesterone than other progestins.[12][13]
Drospirenone was patented in 1976 and introduced for medical use in 2000.[14][15] It is available widely throughout the world.[9] The medication is sometimes referred to as a "fourth-generation" progestin.[16][17] It is available as a generic medication.[18] In 2020, a formulation of drospirenone with ethinylestradiol was the 145th most commonly prescribed medication in the United States, with more than 4 million prescriptions.[19][20]
Drugs.com
was invoked but never defined (see the help page).pmid26598309
was invoked but never defined (see the help page).Ravina2011
was invoked but never defined (see the help page).HatcherM.D.2007
was invoked but never defined (see the help page).RossoZeichner2016
was invoked but never defined (see the help page).